Abstract 1232P
Background
Randomized controlled trials (RCTs) showed survival improvement with neoadjuvant/perioperative ICI + CT in early NSCLC. However, interpretation of the results can be affected by a variable level of uncertainty due to censoring imbalance and vulnerability of statistical conclusions.
Methods
PubMed, Embase and Cochrane were searched until April 2024 for RCTs comparing neoadjuvant/perioperative ICI + CT with neoadjuvant CT in patients with early-stage NSCLC. Individual Patient Data (IPD) curves and the corresponding hazard ratios (HR) were reconstructed from published EFS Kaplan-Meier data from each trial and treatment arm by using an IPD software. Reverse HR (R-HR) was obtained by flipping the status of time-dependent outcome for individual patients (reverse Kaplan Meier method) and were used to estimate censoring imbalance. SIFI was determined by iteratively transferring the best survivors from the experimental arm to the control arm until p≥0.05; conversely, negative SIFI was calculated until p<0.05.
Results
Eight RCTs (n=3387) were included. R-HR analysis showed a trend in increased censoring imbalance in the experimental arm in 1 RCT (NADIM II) and in the control arm in 2 RCTs (NeoTORCH, TD-FOREKNOW), in 1 RCT (RATIONALE-315) censoring imbalance was significantly higher in the control arm (R-HR 1.30; 95% CI 1.02-1.65). Median SIFI was 12 (IQR, 4.25 - 20.25), with absolute weighted SIFI ≤ 2% in 3 RCTs (NADIM II, AEGEAN, Checkmate 816), suggesting a potential vulnerability affecting the significance of results. Table: 1232P
| Study name | N | IPD-HR | R-HR (control vs experimental) | SIFI (%) | Median FUP months (range, if specified) |
| AEGEAN | 740 | 0.70 (0.54 - 0.91) | 0.96 (0.80 - 1.15) | 9 (1) | 11.7 |
| NADIM II | 86 | 0.43 (0.21 - 0.86) | 0.51 (0.23 - 1.13) | 2 (2) | 26.1 (17.4 - 30.9) |
| CheckMate 816 | 358 | 0.66 (0.48-0.91) | 1.06 (0.80 - 1.41) | 5 (1) | 41.4 |
| NeoTORCH | 404 | 0.39 (0.28 - 0.54) | 1.12 (0.86 - 1.47) | 33 (8) | 18.3 |
| KEYNOTE 671 | 797 | 0.57 (0.46 - 0.70) | 0.99 (0.81 - 1.19) | 37 (5) | 25.2 (7.5 - 50.6) |
| CheckMate 77T | 461 | 0.58 (0.44 - 0.78) | 1 (0.78 - 1.28) | 15 (3) | 25.4 (15.7 - 44.2) |
| TD-FOREKNOW | 88 | 0.53 (0.21 - 1.30) | 1.33 (0.81 - 2.19) | -4 (5) | 14.1 (9.2 - 20.9) |
| RATIONALE-315 | 453 | 0.56 (0.40 - 0.79) | 1.30 (1.02 - 1.65) | 16 (4) | 22.0 |
Conclusions
Significant censoring imbalance in the control arm and high survival fragility were reported in 1 and 3 RCTs, respectively, suggesting that informative censoring and survival vulnerability are useful tools to ensure a reliable interpretation of data.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1074TiP - A phase I study of GIGA-564, a minimally blocking anti-CTLA-4 monoclonal antibody
Presenter: James Gulley
Session: Poster session 04
1075TiP - A phase I trial of ATG-101, an investigational PD-L1×4-1BB bispecific antibody, in patients with advanced solid tumors and mature B cell non-Hodgkin lymphomas: PROBE-CN
Presenter: Junli Xue
Session: Poster session 04
Resources:
Abstract
1083P - KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma
Presenter: Reinhard Dummer
Session: Poster session 04
1084P - Phase II study of AI-designed personalized neoantigen cancer vaccine, EVX-01, in combination with pembrolizumab in advanced melanoma
Presenter: Muhammad Khattak
Session: Poster session 04
1085P - Adoptive cell therapy with TCR gene-engineered T cells directed against MAGE-C2-positive melanoma: An ongoing phase I trial
Presenter: Brigit van Dijk
Session: Poster session 04
1086P - Intratumoral (IT) administration of autologous CD1c(BDCA-1)+/CD141(BDCA-3)+myeloid dendritic cells (myDC) with the immunologic adjuvant AS01B plus ipilimumab (IPI) and IV nivolumab (NIVO) in patients with refractory advanced melanoma: A phase Ib clinical trial
Presenter: Manon Vounckx
Session: Poster session 04
1087P - Phase II study of niraparib in patients with advanced melanoma with homologous recombination pathway gene mutations
Presenter: Kevin Kim
Session: Poster session 04
1088P - Molecular profiling and matched targeted therapy for patients with advanced melanoma: Results from part I of the MatchMEL study
Presenter: Andrea Boutros
Session: Poster session 04
1089P - Longitudinal biomarker analysis and outcomes for patients (pts) treated with neoadjuvant nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma
Presenter: Elizabeth Burton
Session: Poster session 04
Resources:
Abstract
1090P - High concurrent interferon gamma signature expression in the primary tumor and lymph node metastasis is associated with superior outcome upon neoadjuvant ipilimumab + nivolumab in stage III melanoma
Presenter: Lotte Hoeijmakers
Session: Poster session 04